BIOMAT Database Logo BIOMAT Database Logo

Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects. 2022

Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.

Allosteric modulation represents an important approach in drug discovery because of its advantages in safety and selectivity. SOMCL-668 is the first selective and potent sigma-1 receptor allosteric modulator, discovered in our laboratory. The present work investigates the potential therapeutic effects of SOMCL-668 on phencyclidine (PCP)-induced schizophrenia-related behavior in mice and further elucidates underlying mechanisms for its antipsychotic-like effects. SOMCL-668 not only attenuated acute PCP-induced hyperactivity and PPI disruption, but also ameliorated social deficits and cognitive impairment induced by chronic PCP treatment. Pretreatment with the selective sigma-1 receptor antagonist BD1047 blocked the effects of SOMCL-668, indicating sigma-1 receptor-mediated responses. This was confirmed using sigma-1 receptor knockout mice, in which SOMCL-668 failed to ameliorate PPI disruption and hyperactivity induced by acute PCP and social deficits and cognitive impairment induced by chronic PCP treatment. Additionally, in vitro SOMCL-668 exerted positive modulation of sigma-1 receptor agonist-induced intrinsic plasticity in brain slices recorded by patch-clamp. Furthermore, in vivo lower dose of SOMCL-668 exerted positive modulation of improvement in social deficits and cognitive impairment induced by the selective sigma-1 agonist PRE084. Also, SOMCL-668 reversed chronic PCP-induced down-regulation in expression of frontal cortical p-AKT/AKT, p-CREB/CREB and BDNF in wide-type but not sigma-1 knockout mice. Moreover, administration of the PI3K/AKT inhibitor LY294002 abolished amelioration by SOMCL-668 of chronic PCP-induced schizophrenia-related behaviors by inhibition of BDNF expression. The present data provide initial, proof-of-concept evidence that allosteric modulation of the sigma-1 receptor may be a novel approach for the treatment of psychotic illness.

UI MeSH Term Description Entries
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000097605 Sigma-1 Receptor A sigma receptor that regulates neuroinflammation, neurotransmitters, neurogenesis, ENDOPLASMIC RETICULUM stress and MITOCHONDRIA function. Receptor 1, Sigma
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D017480 Receptors, sigma A class of cell surface receptors recognized by its pharmacological profile. Sigma receptors were originally considered to be opioid receptors because they bind certain synthetic opioids. However they also interact with a variety of other psychoactive drugs, and their endogenous ligand is not known (although they can react to certain endogenous steroids). Sigma receptors are found in the immune, endocrine, and nervous systems, and in some peripheral tissues. Opioid Receptors, sigma,Receptors, Opioid, sigma,Receptors, sigma Opioid,sigma Receptors,sigma Receptor,Receptor, sigma,sigma Opioid Receptors
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity.
May 2016, CNS neuroscience & therapeutics,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Allosteric modulation of sigma-1 receptors elicits anti-seizure activities.
August 2015, British journal of pharmacology,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Allosteric Modulators of Sigma-1 Receptor: A Review.
January 2019, Frontiers in pharmacology,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
The antipsychotic potential of muscarinic allosteric modulation.
May 2010, Drug news & perspectives,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
The antidepressant-like effect induced by the sigma(1) (sigma(1)) receptor agonist igmesine involves modulation of intracellular calcium mobilization.
August 2002, Psychopharmacology,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
May 2016, The Journal of biological chemistry,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
June 2014, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
June 2017, ACS chemical neuroscience,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Antipsychotic-like effects of a neurotensin receptor type 1 agonist.
May 2016, Behavioural brain research,
Jiali Chen, and Guangying Li, and Pingping Qin, and Jiaojiao Chen, and Na Ye, and John L Waddington, and Xuechu Zhen
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
June 2021, Nature communications,
Copied contents to your clipboard!